Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.

@article{Beltran2014Ganitumab4,
  title={Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.},
  author={Pedro J. Beltran and Frank J. Calzone and Petia Mitchell and Young-Ah Chung and Elaina E Cajulis and Gordon Moody and Brian Belmontes and Chi-Ming Li and Steven L. Vonderfecht and Victor E. Velculescu and Guorong Yang and Jingwei Qi and Dennis J. Slamon and Gottfried E. Konecny},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 11},
  pages={2947-58}
}
PURPOSE Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal antibody against IGF-IR. Here, we explore the therapeutic potential of ganitumab for the treatment of ovarian cancer. EXPERIMENTAL DESIGN The effects of ganitumab were tested in vitro against a panel of 23 established ovarian cancer cell lines. The ability of ganitumab to inhibit IGF-I-, IGF-II-, and insulin-mediated… CONTINUE READING